Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

European Journal of Cancer

Volumn 82, Issue , 2017, Pages 45-55

  Schadendorf, Dirk ^a,b   Long, Georgina V ^c,d,e   Stroiakovski, Daniil ^f   Karaszewska, Boguslawa ^g   Hauschild, Axel ^h   Levchenko, Evgeny ⁱ   Chiarion Sileni, Vanna ^j   Schachter, Jacob ^k   Garbe, Claus ^l   Dutriaux, Caroline ^m   Gogas, Helen ⁿ   Mandalà, Mario ^o   Haanen, John B A G ^p   Lebbé, Céleste ^q   Mackiewicz, Andrzej ^r   Rutkowski, Piotr ^s   Grob, Jean Jacques ^t   Nathan, Paul ^u   Ribas, Antoni ^v   Davies, Michael A ^w   Zhang, Ying ^x   Kaper, Mathilde ^x   Mookerjee, Bijoyesh ^x   Legos, Jeffrey J ^x   Flaherty, Keith T ^y   Robert, Caroline ^z   more..

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Mater Hospital   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f Moscow City Oncology Hospital 62   (Russian Federation)

^g Przychodnia Lekarska NZOZ KOMED   (Poland)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^j VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^k SHEBA MEDICAL CENTER   (Israel)

^l UNIVERSITY OF TÜBINGEN   (Germany)

^m HÔPITAL SAINT ANDRÉ   (France)

ⁿ UNIVERSITY OF ATHENS   (Greece)

^o PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^p NETHERLANDS CANCER INSTITUTE   (Netherlands)

^q ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^r POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^s INSTITUTE OF ONCOLOGY   (Poland)

^t AIX MARSEILLE UNIVERSITY   (France)

^u MOUNT VERNON CANCER CENTRE   (United Kingdom)

^v UCLA MEDICAL CENTER   (United States)

^w UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^x NOVARTIS PHARMA AG   (Switzerland)

^y MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^z INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Dabrafenib; Melanoma; Multivariate analysis; Trametinib; Vemurafenib

Indexed keywords

DABRAFENIB; LACTATE DEHYDROGENASE; TRAMETINIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ARTICLE; CANCER SURVIVAL; CLINICAL OUTCOME; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT DURATION; ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; MALE; MELANOMA; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMIDAZOLES; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; OXIMES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 85021091606     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.05.033     Document Type: Article

References (30)

1. Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386:9992 (2015), 444–451.
2. Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:1 (2015), 30–39.
3. Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:4 (2015), 375–384.
4. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
5. Hodi, F.S., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K.F., McDermott, D.F., et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17:11 (2016), 1558–1568.
6. Ascierto, P.A., McArthur, G.A., Dreno, B., Atkinson, V., Liszkay, G., Di Giacomo, A.M., et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:9 (2016), 1248–1260.
7. Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/k–mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol, 2017, 10.1093/annonc/mdx176 [in press].
8. Robert, C., Karaszewska, B., Schachter, J., Rutowski, P., Mackiewicz, A., Stryakovskiy, D., et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Eur J Cancer, 51(Suppl. 3), 2015 abstr 3301.
9. Weber J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller W, et al. Overall survival in patients with advanced melanoma who received nivolumab vs investigator's choice chemotherapy in the phase 3 CheckMate 037 trial. Oral presentation at: Society for Melanoma Research Congress; November 6–9, 2016; Boston, MA.
10. Schachter, J., Ribas, A., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006. ASCO Meet Abstr, 34(15_Suppl), 2016, 9504.
11. Ascierto, P.A., Ribas, A., Larkin, J., McArthur, G.A., Lewis, K.D., Hauschild, A., et al. Prognostic subgroups and impact of treatment for post-progression overall survival in patients with BRAFV600-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis. Ann Oncol, 27(Suppl. 6), 2016, vi394.
12. Ribas, A., Hodi, F.S., Lawrence, D.P., Atkinson, V., Starodub, A., Carlino, M.S., et al. Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: phase 1 KEYNOTE-022 study. J Clin Oncol, 34, 2016 suppl; abstr 3014.
13. Ribas, A., Butler, M., Lutzky, J., Lawrence, D.P., Robert, C., Miller, W., et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol, 33, 2015 suppl; abstr 3003.
14. Hwu, P., Hamid, O., Gonzalez, R., Infante, J.R., Patel, M.R., Hodi, F.S., et al. Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma. Ann Oncol, 27(Suppl. 6), 2016, vi381.
15. Long, G.V., Grob, J., Nathan, P., Ribas, A., Robert, C., Schadendorf, D., et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 17:12 (2016), 1743–1754.
16. Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371:20 (2014), 1877–1888.
17. Balch, C.M., Gershenwald, J.E., Soong, S.J., Thompson, J.F., Atkins, M.B., Byrd, D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:36 (2009), 6199–6206.
18. Cox, D.R., Oakes, D., Analysis of survival data. 1984, Chapman and Hall/CRC, New York.
19. Therneau, T.M., Grambsch, P.M., Modeling survival data: extending the Cox model. 2001, Springer, New York.
20. Atkinson EJ, Therneau TM. An introduction to recursive partitioning using the RPART routines. Mayo Foundation http://www.mayo.edu/research/documents/biostat-61pdf/doc-10026699. [Accessed 15 February 16].
21. Long, G.V., Weber, J.S., Infante, J.R., Kim, K.B., Daud, A., Gonzalez, R., et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 34:8 (2016), 871–878.
22. Menzies, A.M., Wilmott, J.S., Drummond, M., Lo, S., Lyle, M., Chan, M.M., et al. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer 121:21 (2015), 3826–3835.
23. Larkin, J.M.G., McArthur, G.A., Ribas, A., Ascierto, P.A., Gallo, J.D., Rooney, I.A., et al. Clinical predictors of response for coBRIM: a phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM). J Clin Oncol, 34, 2016 suppl; abstr 9528.
24. Ascierto PA, Dréno B, Larkin J, McArthur GA, Danielli R, Demidov L, et al. Clinical predictors of survival with cobimetinib combined with vemurafenib: pooled analysis from BRIM-7 and coBRIM. Poster presentation at: Society for Melanoma Research Congress; November 6–9, 2016; Boston, MA.
25. McArthur, G.A., Larkin, J.M.G., Ascierto, P.A., Hsu, J.J., Yan, Y., Rooney, I.A., et al. Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF-mutated melanoma patients (pts) with poor and favorable prognosis in the coBRIM phase III study. J Clin Oncol, 34, 2016 suppl; abstr 9530.
26. Weide, B., Martens, A., Hassel, J.C., Berking, C., Postow, M.A., Bisschop, K., et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 22:22 (2016), 5487–5496.
27. Rai, R., McQuade, J.L., Wang, D.Y., Park, J.J., Nahar, K., Sosman, J.A., et al. Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma. Ann Oncol, 27(Suppl. 6), 2016, iv382.
28. Larkin J, Ferrucci PF, Gonzalez R, Thomas L, Maio M, Hill A, et al. Efficacy of nivolumab plus ipilimumab combination in patients with advanced melanoma and elevated serum lactate dehydrogenase: a pooled analysis. Oral presentation at: Society for Melanoma Research Congress; November 6–9, 2016; Boston, MA.
29. Blank C, Ribas A, Long GV, Mortier L, Carlino MS, Lotem M, et al. Impact of baseline serum lactate dehydrogenase concentration on efficacy in the KEYNOTE-006 study of pembrolizumab vs ipilimumab. Poster presentation at: Society for Melanoma Research Congress; November 6–9, 2016; Boston, MA.
30. Long, G.V., Blank, C., Ribas, A., Mortier, L., Carlino, M.S., Lotem, M., et al. Impact of baseline serum LDH concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006. Eur J Cancer, 72(Suppl. 1), 2017 abstr 1141; S122.